Clinical Trial Update: A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy [Phase 3]

View source ↗

Summary

Phase III study evaluating HSK39297 in paroxysmal nocturnal hemoglobinuria patients naive to complement inhibitor therapy has completed. The sponsor is Haisco P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• HSK39297

Snippet

Sponsor: Haisco Pharmaceutical Group Co., Ltd. | Conditions: PNH | Phase 3 | Status: COMPLETED